Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.

about

Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.

Item

http://www.wikidata.org/entity/Q38208275

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Optimized nonclinical safety a ...... rgeting inflammatory diseases.

@en

type

Item

label

Optimized nonclinical safety a ...... rgeting inflammatory diseases.

@en

prefLabel

Optimized nonclinical safety a ...... rgeting inflammatory diseases.

@en

P1476

Optimized nonclinical safety a ...... rgeting inflammatory diseases.

@en

P2093

Alison Wolfreys

http://www.w3.org/2001/XMLSchema#string

Annick Cauvin

http://www.w3.org/2001/XMLSchema#string

Frank R Brennan

http://www.w3.org/2001/XMLSchema#string

Jay Tibbitts

http://www.w3.org/2001/XMLSchema#string

P2860

The accuracy of extended histopathology to detect immunotoxic chemicals

Priming of protective T cell responses against virus-induced tumors in mice with human immune system components

mAbs: a business perspective

Preclinical development of monoclonal antibodies: considerations for the use of non-human primates

Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets

Structural characterization of a human Fc fragment engineered for lack of effector functions

Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies

The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI

IL-23 promotes tumour incidence and growth

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

P304

115-161

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/DDR.21173

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24782266

http://www.w3.org/2001/XMLSchema#string